March 26, 2019
Triplex Meets Primary Endpoint in Phase 2 Clinical Trial, Reduces Rate of Cytomegalovirus (CMV) Complications in Transplant Recipients by 50 Percent
First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem…